Amarantus Bioscience Holdings Inc (AMBS)

[Skeetz99]

Please be careful to draw any conclusions as to how NanoSomix's product has beaten LymPro to the market. The test appears to be very one dimensional as it relates to identifying p-tau as a biomarker (solely). Secondly, Amarantus has aligned with some heavy hitters (Becton and ICON); so these collaborations provide excellent sponsorship that Pharmaceuticals will heed notice to as well. Lastly, I am wondering if NanSomix will peer review the data; as Amarantus has clearly stated they will be doing so in 2015.

Note: Lets see how Jobo spins the NanSomix article into a disaster for Amarantus....always fascinated to constantly hear the negative in everything AMBS produces or executes within their pipeline.

Excerpt from NanoSomiX article:
“Our first blood assay will be available this fall for researchers and pharmaceutical companies that want to use p-tau as a biomarker for drug evaluation or patient sample enrichment in their clinical trials,” said John Osth, President and CEO of NanoSomiX.